Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestors.amgen.com
Amgen Inc. News Releases
Get the latest updates from Amgen Inc. News Releases directly as they happen.
Follow now 47 followers
Latest posts
Last updated 3 days ago
AMGEN AND FOOTBALL LEGEND BARRY SANDERS HIGHLIGHT DANGERS OF BAD CHOLESTEROL IN NEW DOCUMENTARY
3 days ago
The Making of a Heart Attack Educates Viewers About High LDL-C— a...
AMGEN TO PRESENT AT GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
10 days ago
THOUSAND OAKS, Calif. , June 5, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN)...
IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS
14 days ago
Breakthrough Second-Line Treatment Demonstrated Survival Advantage over Standard-of-Care Chemotherapy Late-Breaking Data Presented...
AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
16 days ago
THOUSAND OAKS, Calif. , May 30, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will...
AMGEN TO PRESENT AT THE 2025 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE
about 1 month ago
THOUSAND OAKS, Calif. , May 16, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will...
AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
about 1 month ago
THOUSAND OAKS, Calif. , May 9, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will...
AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
about 2 months ago
THOUSAND OAKS, Calif. , May 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today...
AMGEN ANNOUNCES WEBCAST OF 2025 FIRST QUARTER FINANCIAL RESULTS
about 2 months ago
THOUSAND OAKS, Calif. , April 28, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today...
AMGEN ANNOUNCES $900 MILLION MANUFACTURING EXPANSION, CREATION OF 350 NEW JOBS IN OHIO
about 2 months ago
Total Investment in the State to Exceed $1.4 Billion , 750 U.S...
IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER
2 months ago
First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for...
UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE
2 months ago
Breakthrough CD19+ B-Cell Targeted Therapy Delivered an 87% Reduction in the Risk...
UPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS
3 months ago
Patients Reported Improvement in Ability to Conduct Daily Activities with Twice-Yearly Dosing...